Hospital
Prisma Health-Midlands
Prisma Health-Midlands was paid $28.15M by Medicaid between Jan 2018 and Dec 2024, across 352 billing codes. Its largest line is 11042, Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm — 11% of everything it billed.
33Billing provider infoPRISMA HEALTH-MIDLANDS
SUMTER, SC 29150
SUMTER, SC 29150
33aNPI1326043548assigned 06/15/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$28.15M
24GClaims1,030,157
24DCodes billed352
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#11 of 115
Median peer was paid$2.47M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 142,835 | $3.69M | |
| 2019 | 155,179 | $3.56M | |
| 2020 | 138,753 | $3.41M | |
| 2021 | 166,526 | $4.43M | |
| 2022 | 157,265 | $5.08M | |
| 2023 | 141,197 | $4.49M | |
| 2024incomplete | 128,402 | $3.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 11% | 8,708 | 4,230 | $3.16M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.1% | 54,155 | 45,849 | $1.99M |
| 81001 | 6.0% | 32,828 | 29,108 | $1.70M | |
| 80053 | Comprehensive metabolic panel | 5.0% | 39,528 | 33,304 | $1.40M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.9% | 21,767 | 10,896 | $1.09M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 11,451 | 10,177 | $1.01M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.4% | 30,648 | 9,056 | $963K |
| 36415 | Collection of venous blood by venipuncture | 3.4% | 13,834 | 11,738 | $945K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.2% | 17,876 | 5,634 | $898K |
| 81025 | 3.0% | 16,904 | 15,408 | $833K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.6% | 9,847 | 9,310 | $731K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 8,235 | 5,881 | $715K |
340 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 2.3% | 22,388 | $651K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.2% | 5,328 | $615K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.9% | 3,668 | $546K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 12,907 | $506K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 20,236 | $456K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 5,046 | $453K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.5% | 12,089 | $415K |
| 99284 | Emergency room visit (serious) | 1.4% | 35,504 | $406K |
| 87081 | 1.4% | 4,338 | $391K | |
| 93970 | 1.1% | 1,882 | $305K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,459 | $281K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 9,210 | $270K |
| 87070 | <1% | 1,042 | $249K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 10,226 | $241K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,668 | $233K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,864 | $230K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,831 | $193K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 219 | $188K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,877 | $186K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,330 | $163K |
| 86850 | <1% | 3,152 | $163K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,665 | $154K |
| D1120 | Dental cleaning, child | <1% | 1,688 | $143K |
| 74018 | <1% | 1,983 | $139K | |
| 73130 | <1% | 2,039 | $137K | |
| 71250 | <1% | 1,071 | $135K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 22,929 | $135K |
| 93880 | <1% | 715 | $130K | |
| 77336 | <1% | 619 | $129K | |
| 97161 | <1% | 2,760 | $122K | |
| 73630 | <1% | 2,681 | $120K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,476 | $119K |
| 83735 | <1% | 11,726 | $116K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 923 | $115K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 437 | $113K |
| 86900 | <1% | 4,650 | $109K | |
| 73610 | <1% | 2,034 | $109K | |
| 93922 | <1% | 592 | $104K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,193 | $103K |
| 94060 | <1% | 314 | $99K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,912 | $97K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,461 | $93K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,272 | $89K |
| 71045 | Radiologic examination, chest; single view | <1% | 17,525 | $87K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,190 | $87K |
| 76642 | <1% | 2,134 | $84K | |
| 73564 | <1% | 2,352 | $82K | |
| 73030 | <1% | 2,166 | $77K | |
| 99285 | Emergency room visit (most serious) | <1% | 24,941 | $73K |
| G0378 | Hospital observation service, per hour | <1% | 9,755 | $69K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,169 | $66K |
| 94664 | <1% | 729 | $63K | |
| 80069 | <1% | 2,031 | $61K | |
| 82962 | <1% | 2,192 | $59K | |
| 97162 | <1% | 1,429 | $59K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,784 | $59K |
| 73110 | <1% | 1,131 | $58K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,583 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,774 | $54K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,162 | $53K |
| 77065 | Tomosynthesis, mammo | <1% | 1,422 | $52K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,056 | $51K |
| 10060 | <1% | 132 | $50K | |
| 72100 | <1% | 1,793 | $50K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,625 | $49K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,817 | $48K |
| 88304 | <1% | 936 | $47K | |
| 93925 | <1% | 827 | $46K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,276 | $42K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,017 | $42K |
| 92523 | <1% | 358 | $38K | |
| 76770 | <1% | 502 | $38K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 56,142 | $36K |
| 85027 | <1% | 6,544 | $35K | |
| 12001 | <1% | 244 | $35K | |
| 87210 | <1% | 2,144 | $32K | |
| 20610 | <1% | 308 | $32K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 671 | $28K |
| 73502 | <1% | 1,331 | $27K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,907 | $27K |
| 97116 | <1% | 1,324 | $27K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,696 | $26K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 3,668 | $25K |
| 84702 | <1% | 4,890 | $24K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 889 | $24K |
| 87077 | <1% | 1,995 | $24K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 89 | $23K |
| 84112 | <1% | 107 | $23K | |
| 73140 | <1% | 197 | $22K | |
| 76536 | <1% | 308 | $21K | |
| 97165 | <1% | 647 | $21K | |
| 76801 | <1% | 399 | $21K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,307 | $20K |
| 70486 | <1% | 504 | $20K | |
| 93798 | <1% | 660 | $20K | |
| 81003 | <1% | 1,596 | $18K | |
| 59025 | Fetal non-stress test | <1% | 2,990 | $17K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,115 | $17K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,657 | $17K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 82 | $17K |
| 87807 | <1% | 1,126 | $16K | |
| J3490 | Unclassified drugs | <1% | 7,129 | $16K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,153 | $16K |
| 77066 | Tomosynthesis, mammo | <1% | 189 | $15K |
| 96376 | <1% | 5,942 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,673 | $15K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 543 | $15K |
| 12011 | <1% | 109 | $15K | |
| D0120 | Dental checkup, returning patient | <1% | 614 | $14K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,804 | $14K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 377 | $14K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,727 | $13K |
| 77386 | <1% | 302 | $13K | |
| 73080 | <1% | 187 | $13K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 900 | $12K |
| 11045 | <1% | 1,198 | $12K | |
| D0272 | Bitewings - two radiographic images | <1% | 1,321 | $12K |
| 62323 | <1% | 241 | $11K | |
| 73090 | <1% | 244 | $11K | |
| 86922 | <1% | 264 | $11K | |
| 73562 | <1% | 367 | $10K | |
| D0240 | <1% | 437 | $9K | |
| 85610 | <1% | 13,152 | $9K | |
| 87631 | <1% | 233 | $9K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 4,164 | $9K |
| 88307 | <1% | 232 | $8K | |
| 74178 | <1% | 42 | $8K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 33 | $7K |
| 11043 | <1% | 17 | $7K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,862 | $7K |
| 72050 | <1% | 111 | $7K | |
| 72040 | <1% | 90 | $7K | |
| 86140 | <1% | 1,442 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 84 | $6K |
| 12002 | <1% | 27 | $6K | |
| 73590 | <1% | 233 | $6K | |
| 97750 | <1% | 736 | $6K | |
| 88342 | <1% | 112 | $5K | |
| D2330 | <1% | 2,060 | $5K | |
| 70496 | <1% | 42 | $5K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $5K |
| 72131 | <1% | 446 | $5K | |
| 85379 | <1% | 1,967 | $5K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 13 | $5K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 77 | $5K |
| 73560 | <1% | 156 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 338 | $4K |
| 85730 | <1% | 11,088 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,144 | $4K |
| 82570 | <1% | 1,664 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 117 | $4K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 30 | $4K |
| 97597 | <1% | 104 | $4K | |
| 94726 | <1% | 421 | $4K | |
| G0239 | Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring) | <1% | 137 | $4K |
| 76000 | <1% | 89 | $3K | |
| 82731 | <1% | 14 | $3K | |
| 87088 | <1% | 4,083 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,663 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,986 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,119 | $3K |
| 94644 | <1% | 1,603 | $3K | |
| 80177 | <1% | 408 | $3K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 31 | $3K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 832 | $3K |
| 82550 | <1% | 7,860 | $3K | |
| 88142 | <1% | 207 | $3K | |
| 84145 | <1% | 1,068 | $3K | |
| 93971 | <1% | 29 | $2K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 142 | $2K |
| 93976 | <1% | 1,484 | $2K | |
| 78451 | <1% | 14 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,728 | $2K |
| 84484 | <1% | 14,836 | $2K | |
| 72141 | <1% | 14 | $2K | |
| 82803 | <1% | 270 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,264 | $2K |
| 82272 | <1% | 238 | $2K | |
| 82805 | <1% | 389 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,655 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,138 | $2K |
| 83880 | <1% | 6,126 | $2K | |
| 80176 | <1% | 32 | $2K | |
| 97166 | <1% | 28 | $2K | |
| 77334 | <1% | 19 | $2K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 1,333 | $2K |
| 77001 | <1% | 90 | $2K | |
| 92522 | <1% | 30 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 25 | $1K |
| 70491 | <1% | 13 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,931 | $1K |
| 82077 | <1% | 3,636 | $1K | |
| 36600 | <1% | 56 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 544 | $1K |
| 80076 | <1% | 2,721 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 16 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,789 | $1K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $1K |
| 36430 | <1% | 182 | $984.55 | |
| 72114 | <1% | 14 | $916.52 | |
| 82728 | <1% | 204 | $855.78 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 335 | $826.74 |
| 76775 | <1% | 15 | $797.10 | |
| 75984 | <1% | 282 | $735.53 | |
| 82951 | <1% | 26 | $714.43 | |
| 92610 | <1% | 12 | $696.89 | |
| 71101 | <1% | 12 | $645.46 | |
| 80061 | Lipid panel | <1% | 1,835 | $638.83 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 217 | $629.40 |
| A9270 | Non-covered item or service | <1% | 8,903 | $602.84 |
| 93978 | <1% | 52 | $586.93 | |
| 86901 | <1% | 4,649 | $583.37 | |
| 80164 | <1% | 201 | $578.97 | |
| 83690 | <1% | 12,455 | $564.91 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,531 | $531.78 |
| 87186 | <1% | 3,317 | $475.84 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 15 | $445.16 |
| 83540 | <1% | 438 | $434.66 | |
| 82150 | <1% | 955 | $400.23 | |
| 51702 | <1% | 43 | $395.55 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,639 | $373.55 |
| 84100 | <1% | 1,526 | $366.90 | |
| C2627 | Catheter, suprapubic/cystoscopic | <1% | 15 | $353.60 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 831 | $280.14 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 34 | $270.14 |
| 82042 | <1% | 139 | $261.57 | |
| 97168 | <1% | 65 | $247.79 | |
| 93000 | <1% | 114 | $246.44 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,087 | $234.02 |
| C1769 | Guide wire | <1% | 342 | $221.42 |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 15 | $211.51 |
| 90715 | <1% | 942 | $199.63 | |
| 86318 | <1% | 865 | $193.39 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 211 | $192.71 |
| 97164 | <1% | 164 | $188.81 | |
| 85018 | <1% | 97 | $186.52 | |
| 77300 | <1% | 17 | $167.18 | |
| 87040 | <1% | 2,494 | $152.36 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 349 | $143.31 |
| 82746 | <1% | 43 | $140.09 | |
| 70498 | <1% | 55 | $139.91 | |
| 82607 | <1% | 165 | $115.64 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,414 | $111.52 |
| 84439 | <1% | 882 | $89.61 | |
| 51705 | <1% | 303 | $81.13 | |
| 82247 | <1% | 21 | $77.55 | |
| 82330 | <1% | 39 | $70.49 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 157 | $66.42 |
| 83605 | <1% | 2,780 | $64.15 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,583 | $63.29 |
| 87205 | <1% | 963 | $60.99 | |
| 83655 | <1% | 12 | $48.04 | |
| 85652 | <1% | 367 | $34.86 | |
| 93017 | <1% | 108 | $32.31 | |
| 84436 | <1% | 1,523 | $32.18 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 513 | $29.60 |
| 84156 | <1% | 1,986 | $27.06 | |
| 84550 | <1% | 926 | $25.48 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 409 | $23.54 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 512 | $19.03 |
| 82553 | <1% | 1,635 | $15.45 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 701 | $14.18 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,114 | $11.30 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,140 | $10.74 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 365 | $8.93 |
| 80179 | <1% | 238 | $7.49 | |
| 80143 | <1% | 329 | $7.49 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,759 | $5.96 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,175 | $5.22 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,709 | $2.63 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 57 | $0.00 |
| 82575 | 0% | 116 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 2,830 | $0.00 |
| D1206 | Topical application of fluoride varnish | 0% | 1,434 | $0.00 |
| D2931 | 0% | 1,868 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 104 | $0.00 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 0% | 912 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 197 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 240 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 37 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 387 | $0.00 |
| D2331 | 0% | 1,378 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 107 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 608 | $0.00 |
| 94618 | 0% | 37 | $0.00 | |
| D0230 | Intraoral - periapical each additional radiographic image | 0% | 3,666 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 199 | $0.00 |
| D1351 | Sealant - per tooth | 0% | 67 | $0.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 27 | $0.00 |
| 86780 | 0% | 14 | $0.00 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 28 | $0.00 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 16 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 204 | $0.00 |
| 88341 | 0% | 15 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 221 | $0.00 |
| 86920 | 0% | 70 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 66 | $0.00 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 13 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 19 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 14 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 14 | $0.00 |
| 82952 | 0% | 25 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 13 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 12 | $0.00 |
| D0273 | 0% | 25 | $0.00 | |
| 85045 | 0% | 1,880 | $0.00 | |
| D2932 | 0% | 887 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 4,742 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 535 | $0.00 |
| 51701 | 0% | 153 | $0.00 | |
| D0274 | Bitewings - four radiographic images | 0% | 263 | $0.00 |
| 82010 | 0% | 777 | $0.00 | |
| 84466 | 0% | 332 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 77 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 174 | $0.00 |
| 82009 | 0% | 315 | $0.00 | |
| 94729 | 0% | 348 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 220 | $0.00 |
| 76937 | 0% | 85 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 146 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 71 | $0.00 |
| P9021 | Red blood cells, each unit | 0% | 132 | $0.00 |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 141 | $0.00 |
| 96367 | 0% | 65 | $0.00 | |
| 80074 | 0% | 12 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 88 | $0.00 |
| D2332 | 0% | 321 | $0.00 | |
| 85014 | 0% | 33 | $0.00 | |
| 83970 | 0% | 26 | $0.00 | |
| 94645 | 0% | 12 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 187 | $0.00 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 80 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 48 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 13 | $0.00 |
| D2150 | Silver amalgam - two surfaces, primary or permanent | 0% | 24 | $0.00 |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 60 | $0.00 |
| A4311 | Insertion tray without drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | 0% | 54 | $0.00 |
| 78815 | Positron emission tomography (PET) for limited area imaging | 0% | 12 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 13 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPOWELL, KARLA (ENROLLMENT)